Amgen Company Profile (NASDAQ:AMGN)

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web:
  • Market Cap: $113.69 billion
  • Outstanding Shares: 735,399,000
Average Prices:
  • 50 Day Moving Avg: $161.21
  • 200 Day Moving Avg: $159.24
  • 52 Week Range: $133.64 - $184.21
  • Trailing P/E Ratio: 14.68
  • Foreward P/E Ratio: 12.18
  • P/E Growth: 2.36
Sales & Book Value:
  • Annual Revenue: $22.93 billion
  • Price / Sales: 4.96
  • Book Value: $41.62 per share
  • Price / Book: 3.71
  • Annual Dividend: $4.60
  • Dividend Yield: 2.9%
  • EBIDTA: $12.1 billion
  • Net Margins: 33.59%
  • Return on Equity: 29.42%
  • Return on Assets: 11.47%
  • Debt-to-Equity Ratio: 1.01%
  • Current Ratio: 4.11%
  • Quick Ratio: 3.86%
  • Average Volume: 3.67 million shs.
  • Beta: 1.15
  • Short Ratio: 1.76

Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, March 7th. Investors of record on Wednesday, May 17th will be paid a dividend of $1.15 per share on Thursday, June 8th. This represents a $4.60 annualized dividend and a yield of 2.98%. The ex-dividend date is Monday, May 15th. View Amgen's Dividend History.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) posted its earnings results on Wednesday, April, 26th. The company reported $3.15 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.00 by $0.15. The firm had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.60 billion. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The business's revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.90 earnings per share. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share (EPS) guidance of $12.00-12.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.34. The company issued revenue guidance of $22.3-23.1 billion, compared to the consensus revenue estimate of $23.02 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

21 brokerages have issued 12-month target prices for Amgen's shares. Their predictions range from $159.00 to $209.00. On average, they expect Amgen's stock price to reach $187.00 in the next year. View Analyst Ratings for Amgen.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
  • 2. Cann analysts commented, "Positive data released yesterday for Amgen's cardiovascular drug, Repatha continues to support our growth expectations for Amgen. Amgen announced that four-year follow-up results from the OSLER-1 study were published in JAMA Cardiology. This is the longest PCSK9 inhibitor clinical trial to date. No new safety concerns identified and no neutralizing antibodies observed with cumulative exposure." (3/15/2017)
  • 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
  • 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

Are investors shorting Amgen?

Amgen saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 7,752,548 shares, a decline of 12.3% from the March 31st total of 8,837,674 shares. Based on an average daily trading volume, of 2,515,333 shares, the days-to-cover ratio is currently 3.1 days. Approximately 1.1% of the company's stock are sold short.

Who are some of Amgen's key competitors?

Who owns Amgen stock?

Amgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (0.00%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.58%), Primecap Management Co. CA (0.00%) and Morgan Stanley (0.00%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Primecap Management Co. CA, Old Mutual Global Investors UK Ltd., State Street Corp, Janus Capital Management LLC, Parametric Portfolio Associates LLC, Russell Investments Group Ltd. and APG Asset Management N.V.. Company insiders that have sold Amgen stock in the last year include Annette Louise Such and Cynthia M Patton. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Vanguard Group Inc., Renaissance Technologies LLC, Swiss National Bank, Geode Capital Management LLC, SG Americas Securities LLC and Nordea Investment Management AB. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amgen stock cost?

One share of Amgen stock can currently be purchased for approximately $154.60.

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 10 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $187.00 (20.96% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Credit Suisse Group AGSet Price TargetHold$177.00LowView Rating Details
5/22/2017Leerink SwannSet Price TargetHold$159.00LowView Rating Details
5/22/2017BMO Capital MarketsReiterated RatingBuy$200.00 -> $198.00LowView Rating Details
5/22/2017Jefferies Group LLCReiterated RatingHold$180.00LowView Rating Details
5/19/2017Oppenheimer Holdings Inc.Reiterated RatingOutperform$189.00LowView Rating Details
5/6/2017MizuhoSet Price TargetBuy$195.00LowView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
4/27/2017Cowen and CompanyReiterated RatingBuy$209.00LowView Rating Details
4/25/2017Sanford C. BernsteinReiterated RatingMarket Perform$178.00LowView Rating Details
3/20/2017Goldman Sachs Group IncLower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/15/2017CannReiterated RatingOutperform -> Positive$189.00MediumView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
2/11/2017ArgusSet Price TargetBuy$195.00N/AView Rating Details
1/31/2017Royal Bank of CanadaSet Price TargetBuy$190.00N/AView Rating Details
2/1/2017Bank of America CorpUpgradeNeutral -> Buy$156.68 -> $192.00N/AView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup IncLower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/26/2016Morgan StanleyReiterated RatingOverweight$199.00 -> $198.00N/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00N/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CoReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
8/17/2015Deutsche Bank AGReiterated RatingBuy$195.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
Earnings by Quarter for Amgen (NASDAQ:AMGN)
Earnings History by Quarter for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.17
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.01$3.08$3.05
Q3 20173$2.92$3.16$3.07
Q4 20173$2.80$3.09$2.96
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Next Dividend:6/8/2017
Annual Dividend:$4.60
Dividend Yield:2.98%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:44.92% (Trailing 12 Months of Earnings)
36.92% (Based on This Year's Estimates)
36.25% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 79.04%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoQ3 2017 Earnings Forecast for Amgen, Inc. (AMGN) Issued By William Blair - May 25 at 7:40 AM logoAmgen: Comments On Romo, Biosimilars, And Repatha - Seeking Alpha - May 25 at 1:34 AM logoAmgen, Inc. (AMGN) SVP Sells $451,156.80 in Stock - May 24 at 10:34 PM logoAmgen Inc. (AMGN) Tumbled To Nearly A 4-Month Low On Drug Safety Concerns - May 24 at 3:29 PM logoAmgen’s Repatha Could Gain Market Share in 2017 - May 24 at 3:29 PM logoOsteoporosis Drug Meets Primary and Secondary Endpoints - May 24 at 3:29 PM logoBiosimilars Could Become a Key Long-Term Growth Driver for Amgen - May 24 at 3:29 PM logoAmgen, Inc. to Post FY2020 Earnings of $12.15 Per Share, Leerink Swann Forecasts (AMGN) - May 24 at 3:28 PM logoFY2018 Earnings Forecast for Amgen, Inc. Issued By Jefferies Group (AMGN) - May 24 at 1:28 PM logoWilliam Blair Weighs in on Amgen, Inc.'s Q4 2017 Earnings (AMGN) - May 24 at 9:20 AM logoAmgen, Inc. (AMGN) Given a $159.00 Price Target at Leerink Swann - May 23 at 6:58 PM logoAmgen, Inc. (AMGN) Given a $177.00 Price Target by Credit Suisse Group AG Analysts - May 23 at 6:58 PM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN - PR Newswire (press release) - May 23 at 3:32 PM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMGN) - PR Newswire (press release) - May 23 at 3:32 PM logoAmgen, Inc. (AMGN) Stock Dips on Osteoporosis Drug Disappointment - - May 23 at 3:32 PM logoAmgen: Setbacks, Setbacks, Setbacks - May 23 at 3:32 PM logoQ4 2017 EPS Estimates for Amgen, Inc. Lowered by Analyst (AMGN) - May 23 at 8:40 AM logoAmgen (AMGN) Shares Cross 3% Yield Mark - Nasdaq - May 23 at 7:34 AM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN - May 23 at 7:34 AM logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amgen Inc. - May 23 at 7:34 AM logoQ3 2017 EPS Estimates for Amgen, Inc. Decreased by Leerink Swann (AMGN) - May 23 at 7:18 AM logoBMO Capital Markets Reiterates "Buy" Rating for Amgen, Inc. (AMGN) - May 22 at 9:34 PM logoUPDATE: Amgen Inc. stock drops 2% on drug's cardiovascular risk; no approval expected this year - MarketWatch - May 22 at 3:31 PM logoAmgen Inc. (AMGN) Is Down Sharply On Drug Concerns - Nasdaq - May 22 at 3:31 PM logoAmgen: Another One Bites the Dust? - May 22 at 3:31 PM logoUPDATE: Amgen Inc. stock drops 2% on drug's cardiovascular risk; no approval expected this year - May 22 at 3:31 PM logo[$$] Safety risk for Amgen and UCB's bone drug lifts rival Radius - May 22 at 3:31 PM logoRadius Health Spikes 20% After Amgen Osteoporosis Drug Derailed - May 22 at 3:31 PM logo[$$] Another Gloomy Day for Amgen - May 22 at 3:31 PM logoHere's Why Radius Health Gained as Much as 20.2% Today - May 22 at 3:31 PM logoDefense in the Trader Blitz - May 22 at 3:31 PM logoAmgen's Woes: It Could Always Be Worse! - May 22 at 3:31 PM logoJefferies Group LLC Reaffirms Hold Rating for Amgen, Inc. (AMGN) - May 22 at 12:40 PM logoAmgen, Inc. (AMGN) Stock Dips on Osteoporosis Drug Disappointment - May 22 at 12:30 PM logoAmgen News Has Major Readthrough For Radius Health - May 22 at 11:22 AM logoAmgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis - May 22 at 7:39 AM logoHigher rate of heart problems seen with Amgen bone drug in trial - May 22 at 7:39 AM logoUCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV - May 22 at 7:39 AM logoAmgen Osteoporosis Drug Approval Plan Derailed Over Newly Found Heart Safety Risk Signal - May 22 at 7:39 AM logoAmgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab - Nasdaq - May 20 at 3:34 PM logoRepatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets - May 20 at 3:34 PM logoAmgen Announces Voting Results of Annual Meeting of Stockholders - May 19 at 8:30 PM logoAmgen, Inc. (AMGN) Given "Outperform" Rating at Oppenheimer Holdings Inc. - May 19 at 12:20 PM logoAmgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio - May 19 at 9:34 AM logoAmgen Submits Biologics License Application To The FDA For Erenumab - May 19 at 9:33 AM logoAmgen, Inc. : AMGN-US: Dividend Analysis : May 17th, 2017 (record date) : By the numbers : May 18, 2017 - May 18 at 12:13 PM logoAbbVie: Losing Humira Patent Isn't The End - May 17 at 12:27 PM logoAbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech - May 17 at 12:27 PM logoAmgen, Inc. (AMGN) Stock Has the Cure for Boring Portfolios - May 17 at 10:25 AM logoAmgen Is Priced To Buy - Seeking Alpha - May 16 at 3:34 PM



Amgen (AMGN) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff